Sana Biotechnology

Bret Jensen, a 13-year market analyst specializing in biotech, leads The Biotech Forum, offering a model portfolio, live chat, and weekly research. No positions held in mentioned companies, and no compensation received beyond Seeking Alpha.

Pomerantz LLP investigates claims of securities fraud against Sana Biotechnology, Inc. (NASDAQ: SANA), following the company's announcement to suspend development of SC291 and SC379 programs. Sana's stock price fell $0.37 per share, or 9.84%, to close at $3.39 per share on November 5, 2024.

Sana Biotechnology's stock hit a 52-week low of $2.35, with analysts' mixed ratings and insider selling. The company focuses on cell engineering for unmet medical needs.

HSG Conference's final day focused on HD research basics, treatment approaches, and community involvement, highlighting advancements in huntingtin-lowering drugs and biomarkers like NfL, and emphasizing the importance of participation in observational studies and community support.

Valo Health appoints Brian M. Alexander as CEO, Brett Blackman as COO, and Travis Wilson to its Board of Directors, leveraging AI and data for drug discovery.

Sana Biotechnology's stock hits 52-week low at $2.75, down 20.4% over the past year. The company shifts focus to Type 1 diabetes and B-cell driven autoimmune diseases, deprioritizing SC291 and glial progenitor cell programs. Analysts' ratings vary, with Citi raising its target to $15.00 and JMP Securities downgrading to Market Perform. CFO Nathan Hardy to step down in October 2024, with Dhaval Patel appointed as EVP and CSO. InvestingPro data shows significant stock declines, with RSI indicating oversold conditions, though Sana's liquidity remains strong.

Climb Bio appoints Douglas E. Williams, Ph.D., as Chair of its Board of Directors, succeeding Andrew Levin, who remains a director. Dr. Williams brings over 30 years of biotech leadership experience, including roles at Sana Biotechnology, Codiak BioSciences, and Biogen.